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Abstract 
To stop the spread of future epidemics and meet infant vaccination demands in low- and 
middle-income countries, flexible, rapid and low-cost vaccine development and 
manufacturing technologies are required. Vaccine development platform technologies that 
can produce a wide range of vaccines are emerging, including: (a) humanised, high-yield 
yeast recombinant protein vaccines, (b) insect cell-baculovirus ADDomerTM vaccines, (c) 
Generalized Modules for Membrane Antigens (GMMA) vaccines; (d) RNA vaccines. Herein, 
existing and future platforms are assessed in terms of addressing challenges of scale, cost 
and responsiveness. To assess the risk and feasibility of the four emerging platforms, the 
following six metrics were applied: (1) technology readiness, (2) technological complexity, 
(3) ease of scale-up, (4) flexibility for the manufacturing of a wide range of vaccines, (5) 
thermostability of the vaccine product at tropical ambient temperatures, and (6) speed of 
response from threat identification to vaccine deployment. The assessment indicated that 
technologies in the order of increasing feasibility and decreasing risk are the yeast platform, 
ADDomerTM platform, followed by RNA and GMMA platforms. The comparative strengths 
and weaknesses of each technology are discussed in detail, illustrating the associated 







Developing a vaccine from concept to market costs $200-$500 million, and takes 5-18 years 
[1–5].  Additionally, it costs an estimated $50-$700 million to construct, equip and 
commission a vaccine manufacturing facility, taking on average 7 years [1,5–7], while the lead 
time to manufacture a vaccine ranges between 0.5-3 years [1,8].  
To better understand these high costs and lengthy development times, existing vaccine 
manufacturing processes are reviewed. One of the earliest viral vaccine mass-production 
technologies, developed in the 1940s, involves the parallel use of many embryonated hens’ 
eggs as “mini-factories” for influenza vaccines manufacturing [9,10]. Here, fertilized hens’ 
eggs are inoculated with the virus and are incubated to allow viral replication. Next, the 
contents of the eggs are pooled, the virus is separated, purified, in some cases inactivated, 
formulated, filled in vials or syringes and packaged [9,10]. The mean estimated yield is one 
vaccine dose per 1 to 2 eggs [10]. This manufacturing technology is well-established and still 
widely used. However, it has the following disadvantages: (1) the production capacity can 
be restricted due to limited egg availability, especially due to their susceptibility to potential 
pandemic influenza strains; (2) the viruses propagated in eggs might antigenically differ 
from wild-type viruses and might not induce the desired immune response; (3) induction 
of egg-related allergies in some patients [9,10]. To address some of these drawbacks, animal 
cell culture-based viral vaccine manufacturing technologies were developed. For this, 
animal cells are cultured in vitro and infected with the virus. The virus replicates within the 
cells and can also lyse them. Next, the remainder of the cells are lysed, the virus is separated 
using microfiltration or disk-stack centrifugation, and the virus is inactivated using heat or 
chemical agents (e.g. formaldehyde, β-propiolactone, or aziridines) [7]. The genetic material 
is subsequently broken down with nuclease enzymes and the antigen is purified using a 
combination of ultra-filtration and chromatography techniques [7]. The purified antigen is 
formulated into a vaccine, it is then filled into vials or syringes and packaged [7]. Animal cell-
based vaccine production technologies are associated with: (1) high production costs, (2) 
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low growth rates, (3) high contamination risks, requiring high levels of sterility, and (4) 
difficulties in genetically engineering cells for improved production. Both egg and animal 
cell culture grown viruses are in some cases broken down into subunits with antigenic 
properties, rendering them replication deficient and further reducing the disease-causing 
potential of viruses. Besides inactivated and subunit antigens, intact live viruses attenuated 
by passage in a foreign host can also be formulated into vaccines. Live attenuated viral 
vaccines generally induce a stronger and long-lasting vaccination effect but harbour a 
higher disease-causing potential [11,12].  
Whole bacterial vaccines are manufactured by growing the pathogenic bacteria in the 
appropriate culture medium, separation from the culture media by filtration and/or 
centrifugation, and formulation commonly accompanied by lyophilization [7,12–14]. Whole 
bacterial vaccines can consist of either live attenuated bacterial cells or inactivated bacterial 
cells, the former being more common, as these offer a more potent vaccination effect [7,11,15]. 
Bacterial subunit vaccines have also been developed and these can be divided into 2 broad 
categories: toxoid (detoxified toxins) vaccines and capsular polysaccharides vaccines. A 
variation of these are the conjugate or glycoconjugate vaccines, which consist of an antigen 
(often the bacterial polysaccharides) covalently attached to a carrier protein (e.g. tetanus 
toxoid or CRM197), yielding a more efficacious vaccine [11,12]. Subunit vaccines tend to induce 
lower levels of immunogenicity and vaccination effects compared to live attenuated 
vaccines [11,12]. 
The protein antigens from both viruses and bacteria can be recombinantly produced in the 
following host organisms with increasing complexity and costs: (1) Escherichia coli, (2) 
yeast, (3) insect cells and (4) animal cells [7,16–19]. All the vaccine manufacturing technologies 
mentioned so far were developed and applied for producing one specific vaccine or a 
narrow set of vaccines. Thus, none of these technologies can readily be used to produce a 
wide range of antigens within lead times of below 2 months at costs of around $1 per 
vaccine dose. This is especially important for supplying vaccines at low cost for infant and 
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early childhood vaccination in low-income countries, and responding quickly to new threats 
in regional outbreaks, such as the 2014 West Africa Ebola outbreak and the 2015–2016 Zika 
epidemic. To address these pressing needs, new vaccine platform technologies are being 
developed which can enable rapid and low-cost process development and scale-up [7], such 
as (1) humanised, high-yield yeast platform for recombinant protein vaccine production; 
(2) insect cell-baculovirus platforms for ADDomer-based and VLP vaccine production; (3) 
Outer membrane vesicle (OMV) and GMMA vaccines manufacturing; (4) RNA vaccines. 
These four platform technologies were chosen based on their low technological complexity, 
scalability, flexibility for producing a wide range of vaccines and potential thermostability 
of the formulated product. Compared to other vaccine platform and expression technologies 
such as peptide vaccines [20–22], recombinant protein expression in mammalian cells [7,17], 
recombinant protein expression in E. coli [7,17], budded virus-like particles [23,24], 
recombinant protein expression in avian embryos and related cell lines [25], exosome-based 
vaccines [26,27], the four platform technologies chosen in this study satisfy the above 
requirements to a much higher extent [7,17,23,25–27]. In addition, these 4 platforms, can exhibit 
self-adjuvancy: the ADDomerTM and GMMA can be programmed to also display adjuvant-
like entities on their surface; the humanised, high-yield yeast platform can produce proteins 
with adjuvant function and RNA molecules can have self-adjuvant properties. Herein, these 
four emerging vaccine platform technologies are comparatively evaluated for rapidly 
producing a wide range of vaccines at low costs. 
 
2. Overview of the four vaccine platform technologies  
Common examples of recombinant vaccines expressed in conventional yeast and insect 
cells, as well as OMVs and nucleic acids vaccines are shown in Table 1. These existing 
expression systems and vaccine technologies are related, and can be considered proxies, to 
the 4 emerging platform technologies. These proxies indicate the feasibility of producing 




Table 1. Examples of vaccines produced using the following proxies for emerging vaccine 
technologies: yeast expression system, insect cell expression system, OMV-yielding bacteria 


















































































* These vaccine expression systems and platform technologies were used as proxies for the 
4 emerging technologies as follow: yeast expression system for the humanised, high-yield 
7 
 
yeast platform; the insect cell expression system for the insect cell-baculovirus ADDomerTM 




Figure 1 shows a generic overview of vaccine manufacturing processes, and specific 
differences in the Bioprocessing segment (Upstream processing, Mid-stream bioprocessing 
and Downstream separation and purification) will be highlighted for the four vaccine 
platforms and illustrated in Figures 2 and 3. A generic overview of the formulation, quality 
control, filling, capping & sealing, labelling and packaging operations is described below.  
The aims of the formulation process are: (i) to maintain the structure and stability of the 
active ingredient or ingredients and by this maintaining the potency of the vaccine; (ii) 
increase the shelf-life of the vaccine product; (iii) to enhance the potency of the vaccine by 
adding adjuvants which are stimulating the immune response; (iv) to minimize potential 
negative side-effects; (v) and in case of RNA vaccines to enhance the uptake of the RNA by 
the cells of the body which will produce the antigen [7]. 
For formulation, antigens can be adsorbed to aluminium compounds, (e.g. aluminium 
hydroxide) [7]. New adjuvants, such as toll-like receptor agonists (e.g. monophosphoryl lipid 
A and immunostimulatory CpG-motif oligonucleotides) were shown to enable faster 
protection and improved efficacy [7]. Preservatives (e.g. mercury-containing thimerosal) 
were also added to vaccines, however, these preservatives are not used in most modern 
formulations, because the sterility of the manufacturing technique was improved and 
preservatives were no longer needed [7]. Vaccines can be monovalent (containing a single 
strain of a single antigen), polyvalent (containing two or more strains or serotypes of the 
same antigen) or combination vaccines (mix of monovalent and/or polyvalent vaccines 
against more than one disease or multiple strains of an infectious agent). Vaccines are 
commonly formulated in the liquid phase, however, vaccines are also lyophilized to increase 
their shelf-life [7,40]. Through and after formulation the following parameters are kept within 
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well-controlled optimal ranges: solution pH, ionic strength, redox potential, concentration, 
and temperature [7]. 
For quality control, vaccine active ingredients are characterized structurally, (e.g. amino 
acid composition, partial amino acid sequencing, peptide mapping, lipid and carbohydrate 
structure, buoyant density, and epitope characterization) using amino acid sequencing, 
Western blotting, gel electrophoresis and HPLC. Additionally, the antigenicity and sterility 
are also routinely checked before formulation. For the formulated vaccine, protein and 
aluminium content, pyrogenicity, and in vivo potency (determined as ED50) are tested. 
Additionally, for quality control, the following parameters are measured and kept within 
optimal ranges throughout the manufacturing process: temperature, pressure, pH, electric 
conductivity, concentration of various components, homogeneity, presence of chemical and 
biological contaminants, etc. [7]. 
After the formulated product has passed quality control, it is filled into sterile glass vials, 
plastic vials, plastic syringes, glass bottles or plastic bottles [7]. Next, vials are capped, sealed, 
labelled and  packaged for distribution [7]. 
 
Figure 1. Generic overview of vaccine manufacturing processes. 
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The key challenges for yeast platforms are: 1) different glycosylation patterns compared to 
human cells [41–43]; 2) the specific productivity is low[44–46], and 3) for many vaccines it is 
necessary for the recombinant protein antigens to assemble into VLPs for increasing the 
potency of the vaccination [7,47]. To address these challenges high-yield humanized yeast-
based expression platforms are being developed by over-expressing chaperones [44–46]. To 
change the high-mannose profile of yeast to the human-type complex glycan pattern, the 
glycosylation pathways are genetically altered in S. cerevisiae, H. polymorpha and P. pastoris 
[42,43]. The yeasts glycoengineered so far express and secrete most recombinant proteins at 
titres below 1 g/L [48,49] and some at 4-5 g/L [50]. Additional yield-increasing genetic 
engineering is required to reach the secretion levels reported in non-glycoengineered P. 
pastoris of up to 35 g/L and 20 g/L, using methanol-induction and methanol-free processes, 
respectively (source: Purkarthofer T. Pichia pastoris protein expression services. Austria: 
VTU Technology GmbH; 2018. Available from: https://www.vtu-
technology.com/Downloads/files/VTUTechnologyDownloads/VTUTechnologyFolder.pdf)
. To avoid the need for self-assembly of recombinant antigenic proteins into VLPs, the 
immunogenicity of monomeric heterologous antigens could be increased by linking it to a 
highly immunogenic protein domain or by using an appropriate adjuvant [51].  
 
3.1. Upstream and mid-stream processing 
The manufacturing process for humanised, high-yield yeast-based vaccine production is 
illustrated in Figure 2A, based on HBsAg antigen production in S. cerevisiae. The humanized 
yeast would be cell banked and expanded similarly to conventional yeast [7].  
For humanized yeast-based recombinant antigen production, standard yeast bioprocesses 
can be employed. The antigen gene promoters on the plasmid are typically derived from 
constitutive glycolytic genes, thus, antigen expression is proportional to glucose 
consumption, and biomass growth [7]. To minimize episomal plasmid loss and consequent 
yield decrease, plasmid retention is monitored during the process and a selection pressure 
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is applied [7]. The final fermentation culture harvest is also tested for microbial purity [7]. 
Yeast-based production systems inherently do not bear the risk of contamination with 
human or animal viruses, and thus, do not require specific testing in this regard [7]. The 
entire culturing cycle, from thawing to the end of the batch-fermentation takes 1 week. 
 
3.2. Separation, cell lysis and purification 
The downstream processes for proteins produced using humanized yeast are similar to 
protein separation and purification from conventional yeast fermentation [7]. The 
separation downstream of yeast-based production, can be substantially simplified and 
made more economical compared to animal cell-based production, due to: (1) potentially 
high recombinant protein expression and secretion yields by yeast; and (2) low amounts of 
secreted native host-cell yeast proteins. However, the expression and secretion yields still 
need to be increased in glycoengineered yeast to reach the levels reported in non-
glycoengineered P. pastoris of up to 35 g/L (source: Purkarthofer T. Pichia pastoris protein 









Figure 2. Operation scheme for the manufacturing of protein vaccines in humanised, high-
yield yeast and in insect cell platforms. A. Recombinant protein vaccines production in 
humanised, high-yield yeast. Human-like complex glycosylation has been reported in yeast 
[52], however, this and high-yield secretion is not yet implemented at production-scale [7,52–
54]. B. Bio-manufacturing of recombinant ADDomerTM multi-antigen vaccines using the 
MultiBacTM insect cell–baculovirus expression system [55–57]. The process was scaled up here 
based on recombinant HA protein expression for influenza vaccine manufacturing [10,58,59]. 
The grey arrows indicate the feeding back of excess insect cells from the 2500 L production 
bioreactor into the upstream process prior to viral infection. 
 
4. Insect cell-baculovirus platform for recombinant vaccine manufacturing 
Baculoviruses, a family of large double-stranded DNA insect viruses, can accommodate 
multiple additional foreign genes and are commonly used for recombinant protein 
production in insect cell lines[16,17]. Molecular cloning methods are commercially available 
for the rapid generation of baculovirus vectors [17,60], including the CRISPR-Cas9 technology 
[61], within 1 day. However, selection of the recombinant baculovirus that contains the gene 
of interest by plaque purification usually takes about 1 week [60]. To alleviate plaque 
r--- -- ----------------7 
l_c~: 0 ~~~ ""'===cc'. _::i';;~:~n----s~:=~<>:_J 
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selection and purification recombinant baculovirus are commonly generated using a 
progenitor baculoviral genome in form of a bacterial artificial chromosome (BAC) and Tn7 
transposition in E. coli cells [62–64]. 
Insect cell cultures have the following advantages for recombinant protein production: (1) 
higher robustness than animal cell lines [16,17], for large volume culture [16]; (2) effective 
baculovirus vector construction techniques [17,60,61,64]; (3) S2 stably modified insect cells can 
be grown in continuous mode in perfusion cultures [16]; (4) proven industrial scale 
applicability for recombinant protein and vaccine production [16,17]; (5) baculoviruses do not 
represent a human health risk [16].  
The growth rate of insect cells is higher than animal cells but lower than yeast or bacteria 
[17]. Insect cell cultures have the following limitation for recombinant protein production: 
(i) cannot synthesize the mammalian-specific complex glycan structures [16,17,58], this 
however was improved recently by baculoviral systems outfitted with functions to mimic 
human glycosylation [65–67] (ii) higher vaccine manufacturing costs, comparable to animal 
cell culture vaccine manufacturing costs [17].  
In order to apply the insect cell-baculovirus expression system to the production of a wide 
range of vaccines, the MultiBacTM [55,64,68,69] and ADDomerTM [57] multiprotein expression 
platforms can be employed. MultiBacTM offers a simple and versatile method for generating 
recombinant baculovirus DNA to express VLP multiprotein complexes in insect cell culture 
[55,68,69]. ADDomerTM is a synthetic multiprotein scaffold derived from a VLP from the human 
adenovirus serotype 3, produced at high yields using MultiBacTM [57,70]. ADDomerTM is 
composed of ~60 kDa protein subunits (protomers) which self-assembles into pentameric 
protein complexes (pentons) of ~300 kDa. Twelve of these pentons then form the 
ADDomerTM, which has a total a molecular mass of ~3.6 MDa. The ADDomerTM protein 
scaffold can present up to 360 genetically encoded antigenic determinants (aka. epitopes) 
on its surface [57], including purification tags (e.g. biotin, chitin binding protein, Myc tag and 
preferentially the histidine tag for production scale) to facilitate downstream purification 
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[56,57]. ADDomerTM was chosen as the next-generation vaccine platform to represent insect 
cell-baculovirus expression system because: (1) it is highly customizable to display a variety 
of antigenic peptides, proteins and protein domains with lengths of up to 200 amino acids 
on its surface; (2)  it can be rapidly re-configured using the MultiBacTM system; (3) it consists 
of copies of adenoviral penton base proteins which spontaneously form highly stable VLPs; 
(4) it has a size which is similar to a virus, enhancing its immunogenicity; (5) it can harbour 
adjuvant-like epitopes; (6) it is non-replicative and does not carry genetic material; (7) it 
can easily be produced at industrial scale; (8) it is thermostable and independent of a cold 
chain, an advantage in low- and middle-income countries [57]. 
Here, the process for manufacturing multiprotein complexes, such as ADDomerTM, in insect 
cells is described. The scaling-up of the ADDomerTM manufacturing process was based on 
influenza virus hemagglutinin (HA) production for Flublok® vaccine manufacturing, since 
HA multimers have a similar size to ADDomerTM [71,72]. 
 
4.1. Upstream and mid-stream processing 
The ADDomerTM is expressed in Hi5 or Sf21 insect cells from the MultiBacTM expression 
vectors, and for this, the cells and baculovirus are expanded [55–57]. 
Following the expansion of insect cells in small and medium scale bioreactors, cells are 
transferred into the production bioreactor. Prior to infection, excess cells from the 
production bioreactor can be fed back into the upstream process, as indicated by the grey 
arrows in Figure 2B. After the insect cells have divided and reached a density of around 0.5–
0.9×106 cells/ml, the baculovirus is added at an MOI between 0.1-1, such that the cell 
population can double at least once post-infection [55,56]. The added viruses infect the insect 
cells and the ADDomerTM is expressed and remains inside the cells [56,57]. Virus expression 
can be monitored every 12 or 24 hours by the use of expression markers (e.g. yellow 
fluorescent proteins) or by monitoring cell densities [56]. The cells should be harvested once 




4.2. Separation and Purification 
The infected cells are harvested using centrifugation, in a disk stack centrifuge [10,59]. The 
ADDomerTM is extracted from the cells using non-ionic surfactants (e.g. sodium 
deoxycholate, sodium dodecylsulfate, polysorbates and Triton X-100) and then clarified 
using depth filtration [10,56–58]. During depth filtration, the cellular debris and other 
contaminants are retained by the depth filter and clarified solution containing the 
ADDomerTM passes through the filter. 
The clarified solution from the depth filtration step is passed through an ion-exchange 
chromatography column. The ADDomerTM protein can be bound on a cation-exchange 
column using a buffer with a pH below the ADDomer’s isoelectric point (pI), and eluted with 
a buffer with a pH above this pI value. Next, affinity chromatography can be used to further 
purify the ADDomerTM based on the specific interaction between the tag of the ADDomerTM, 
added during the molecular cloning, and the coating of the chromatography column [56,57]. 
Following the two column chromatography steps, a membrane filtration follows whereby 
residual DNA is removed using a Q-membrane [10]. Next, the buffer composition of the 
ADDomerTM solution is brought to its final state using ultrafiltration [58].  
 
5. Outer membrane vesicle vaccines, Generalized Modules for Membrane Antigen 
vaccine manufacturing 
Outer membrane vesicles (OMVs) are naturally generated by all gram-negative bacteria 
during their growth [73,74]. Gram-positive bacteria [75,76], mycobacteria [77], and archaea [78] 
can also naturally release OMVs. OMVs are spherical entities of endocytic origin with 
diameters normally ranging between 20–250 nm [73,74]. These virus-sized lipid bilayer 
vesicles with embedded proteins can be highly immunogenic [74,79,80]. OMV-based vaccines 
can be produced by: (a) culturing wild-type bacteria which naturally secrete OMVs [74], (b) 
detergent extraction using sodium deoxycholate in the presence of EDTA [33,81],  and (c) 
15 
 
culturing genetically altered bacteria for enhanced OMV production [81–83]. Detergent 
extraction removes reactogenic or toxic lipopolysaccharide [74,81,84], but has the following 
disadvantages: (1) loss of negatively charged surface antigens [74,84]; (2) OMVs can aggregate 
and be heterogeneous in size, losing a fraction of OMVs during sterile filtration [84,85]; (3) 
contamination of OMV vaccines with cytoplasmic proteins due to bacterial cell lysis [81,86]. 
To overcome these limitations, OMV-generating bacteria are genetically engineered to 
improve OMV vaccine production.  These genetic engineering modifications can include: (1) 
altering the bacterial lipopolysaccharide biosynthesis pathway to reduce endotoxicity and 
reactogenicity; (2) overexpression of antigens; (3) simultaneous expression of multiple 
antigens and antigenic variants; (4) retention of secreted antigens in the outer membrane; 
(5) enhancing OMV generation by removing outer membrane anchor proteins; (6) removal 
of immune-modulating components which could trigger an undesired type of immune 
response; and (7) inclusion of antigens from pathogens other than the host OMV producing 
strain [74,82]. The integrity and attachment of inner and outer cell wall membranes are 
normally regulated by the Tol-Pal system, and modification of this pathway can be exploited 
to enhance OMV generation [73,87].   
Generalized Modules for Membrane Antigens (GMMA) are OMVs engineered to enhance 
native OMV formation (by deletion of the gna33 in meningococcus and tolR in Shigella 
sonnei and Salmonella), reduce reactogenicity and toxicity (by modifying the acylation 
pattern of lipid A) and over-express immunogenic antigens, [80,83,88]. GMMA contain 
pathogen-associated molecular patterns, including toll-like receptor ligands, which can act 
as self-adjuvants in the immune responses they elicit [87]. GMMA are highly immunogenic 
[80,88], effective, have low reactogenicity, are safe, and can be manufactured at low cost in a 
scalable process [80,83,89,90]. The main limitation of GMMA is that it cannot perform human-
like post-translational modifications (e.g. glycosylation). GMMA production has already 
been scaled up for GMP-quality production using Shigella sonnei and nontyphoidal 
Salmonella vaccines [80,83]. Here, GMP-quality GMMA production in Shigella sonnei is 
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described, because this GMMA-based vaccine is developed to the most advanced stage, 
shown to be safe and immunogenic in clinical trials for adults. The production time from 
thawing of the inoculum for fermentation to final purified GMMA was 3 days and thus, 
depending on the size of the vaccine dose, a relatively small production facility with a 500 
L fermenter could produce in excess of 100,000,000 doses of vaccines per year [80]. The 
operation scheme for the manufacturing of OMV vaccines exemplified by GMMA is shown 
in Figure 3A below. 
 
5.1. Upstream and mid-stream processing 
The bacterial strains of interest were genetically engineered to obtain the desired 
properties for GMMA vaccine production. For this, in Shigella sonnei the tolR, galU and 
msbB1 genes were replaced by antibiotic selection markers [91]. For GMMA vaccine 
production in Salmonella, the tolR, msbB, htrB and pagP genes can be deleted and replaced 
by antibiotic selection markers [90]. The obtained bacterial strains are stored in a 2-tiered 
cell bank and then expanded for production. Compared to animal cells, bacteria grow faster 
and can be cultured in larger volume bioreactors, because bacterial cells are more robust 
and can withstand higher pressure and stirring rates compared to animal cells [13]. 
Once the required inoculation volume was obtained, bacteria are seeded into the fed-batch 
production bioreactors. Bacterial fermenters can have a volume of several hundreds of 
cubic meters, and fermenters with volumes as large as 2000 m3 were also described [13]. 
Once the bacteria reach the stationary growth phase, the broth is transferred to the 
downstream purification phase. 
 
5.2. Separation and Purification 
The GMMA produced during fermentation are released into the fermentation broth, and are 
separated from other broth components using two consecutive TFF steps:  microfiltration 
and ultrafiltration [80]. In the first microfiltration step, the bioreactor is connected to the TFF 
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system and is used as a recirculation tank, thereby bacteria are removed from the broth and 
the GMMA remains in the broth [80]. The culture supernatant is concentrated three times and 
then a discontinuous diafiltration is carried out against 5 volumes of buffer, relative to the 
3-fold concentrated supernatant volume [80]. In the second ultrafiltration step, a substantial 
part of the soluble proteins and nucleic acids are removed. Next, the GMMA solution is 





Figure 3. Operation scheme for the manufacturing of Generalized Modules for Membrane 
Antigens (GMMA) and RNA vaccines. A. GMMA vaccine production using gram-negative 
bacteria. GMMA are released constantly during bacterial culture and are separated using 
two sequential TFF steps [80]. B. RNA vaccine production using in vitro transcription. The 
self-replicating RNA, which encodes the antigen of interest, is transcribed from a DNA 
template using in vitro transcription, 5’ capped co-transcriptionally, the template DNA is 
digested and then purified using TFF [92,93]. 
 
6. RNA vaccine manufacturing  
Nucleic acid (DNA or RNA) vaccines encode the antigen, and this vaccine antigen is 
produced in the cells of the patient. This way, a wide range of antigens can be expressed in 
the human body with the correct human-specific post-translational modifications. Large-
scale manufacturing of RNA molecules or vaccines is uncharted and can pose challenges. 
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Currently there are no regulatory approved RNA vaccines, however, RNA antisense 
oligonucleotides and aptamer therapeutics are already clinically approved for the 
modulation of protein expression [94,95]. Short interfering RNA (siRNA) therapeutics are also 
being developed [95–97]. These RNA therapeutics are considerably shorter in length than RNA 
vaccines, however, these open avenues for clinically approving RNA vaccines. RNA vaccines 
are currently being tried clinically [98,99]. The efficiency of RNA vaccines can be improved 
when self-replicating RNA vectors are used instead of mRNA based vaccines [100,101]. Thus, 
current research focuses on using RNA-dependent RNA polymerase (aka. replicase) based 
RNA vaccines [102–104]. In the case of these replicase-based RNA vaccines, first the replicase 
is expressed and this allows the amplification of RNA template [100,101]. Non-viral delivery 
methods (e.g. nanoparticulate polyplex polyethylenimine (PEI) [105,106]) are preferred for 
RNA vaccines due to lower cost, ease of large-scale production, and improved safety 
potential [107–109]. 
Indeed, RNA vaccines were delivered into the cytoplasm using nanoparticulate cationic 
polyplexes[105,106] or liposomal formulations. The fully synthetic manufacture of RNA and 
ease of production allows the generation of thousands of doses within weeks after emerging 
pathogen identification. Constructs targeting strain diversity or multiple infectious disease 
targets can easily be combined. In addition, low infrastructure and equipment costs make it 
feasible to establish manufacture in low-income settings. Hereby, self-replicating RNA 
vaccine manufacturing was chosen for further analysis due to the ease of delivery using 
polyplexes or liposomes [110], effectiveness and non-mutagenic properties of self-replicating 
RNA vaccines, in comparison to DNA vaccines. The active pharmaceutical ingredient of the 
proposed RNA vaccine is a self-replicating RNA molecule (aka. RNA replicon) based on the 
alphaviral genome. This RNA molecule is 9000–12000 nucleotides long and encodes: (1) a 
non-structural protein that self-cleaves to release the helicase and replicase proteins 
required for replicon RNA duplication and (2) the antigen gene of interest. Flanking these 
coding genes, the replicon RNA also contains a 5’ untranslated region (UTR), a 3’ UTR, a 5’ 
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capping sequence, and ploy(A) tail sequence. The self-replicating RNA molecule is produced 
using a cell-free in vitro transcription reaction, as illustrated in Figure 3B. 
 
6.1. Upstream and mid-stream processing 
First, the plasmid DNA which encodes the full length of the RNA replicon is created, by 
inserting the antigen-encoding gene at the correct location in the RNA replicon expressing 
sequence [92]. The RNA replicon is under the control of the T7 promoter and hence it is 
transcribed using the T7 RNA polymerase. The plasmid DNA is amplified in Escherichia coli, 
purified and linearized using two restriction enzymes [92]. 
The cell-free in vitro transcription (IVT) reaction, transcribes the replicon RNA from the 
DNA template using the T7 RNA polymerase enzyme and yields a complex mixture of DNA, 
RNA and protein enzymes [92]. The 5’ end of the RNA replicon can be capped during IVT by 
supplementing the reactions with m7GpppG cap structure analogues and by keeping the 
molar ratio of the cap molecule high relative to the first nucleotide (i.e. GTP) of the RNA 
sequence [92,111,112]. Alternatively, RNA can be capped in a separate step using vaccinia virus-
derived capping enzyme. Here, potential cost trade-off emerges between the use of costly 
cap analogues in a single IVT reaction versus the use of a cheaper capping reaction that 
requires the introduction of an additional enzymatic manufacturing step. 
The role of the 5’ cap in RNA vaccines is to: (1) prevent degradation by exonucleases, (2) 
promote translation, and (3) evade the innate immune response against RNA molecules [113]. 
The 3’ end of the RNA replicon can be polyadenylated during IVT by encoding the poly(A) 
tail on the DNA template [92]. DNAse I enzyme is added to the IVT reaction mixture to digest 
the template DNA molecules [92].  
 
6.2. Separation and Purification 
The replicon RNA molecule can be separated from the reaction mix using TFF based on size 
differences using polysulfone, polyethersulfone and polyethersulfone filter membranes 
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modified for increased hydrophilicity [93]. Smaller molecular weight impurities (e.g. 
ribonucleoside triphosphates, small nucleic acid fragments, amino acids, etc.) pass through 
this membrane. The transmembrane pressure during TFF is normally around 2 psi (13790 
Pa) and the shear rate is around 800 s-1 [93]. During TFF, buffer exchange (dialysis) can also 
be carried out, by flowing a new buffer into the TFF hollow fibre filter. The buffer is typically 
replaced with a buffer pH of around 8 with a total salt concentration of around 250 mM [93]. 
The total volume increase of the reaction mix during TFF is between 5 and 10 fold, a ratio 
of about final to initial volume of 8:1 is advantageous [93]. 
 
7. Discussion and technology comparison 
Conventional vaccine manufacturing technologies are limited to producing only one vaccine 
or a very narrow range of vaccines, thus individual manufacturing processes need to be 
developed for each vaccine, making vaccine manufacturing process development costly and 
time-consuming. However, the cost of capital as well as construction time, and regulatory 
risk can be reduced, by installing single-use, disposable manufacturing equipment, while 
increasing flexibility [1,7,114,115]. Additionally, constructing manufacturing facilities in low- or 
middle-income countries, where vaccine demand is the highest, has the following 
advantages: lower real estate costs, lower construction material and construction labour 
costs, lower costs for low-skilled labour, lower costs for transporting the vaccine products 
to the communities in need of vaccination. However, this might require the import of 
specialized equipment, raw materials and high-skilled labour from developed countries. 
Moreover, vaccine-generated revenues are low due to: (a) insufficient funding available to 
cover vaccination costs in developing countries, and (b) epidemics vanishing by the time 
vaccines are made available [116]. 
The 4 new platform technologies described in sections 3, 4, 5 and 6 can be cost-effectively 
implemented using the above-described cost reduction strategies. More importantly, these 
can operate at low cost, with the flexibility to produce a wide range of vaccines for: (a) 
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stopping the spread of future epidemics in low and middle-income countries by delivering 
100,000 doses of vaccines within weeks after the identification of a new pathogen and, (b) 
allowing the immunization of 60 million infants per year at a cost of approximately $1 per 
dose.  When reducing costs to ~1 $/dose, the last part of the manufacturing process (i.e. 
formulation, filling into the final delivery form, sealing, labelling and packaging) forms a 
fixed cost per dose which may come to dominate the total cost. Therefore, measures should 
be taken to reduce this fixed cost component. 
To estimate the overall risk and feasibility of these 4 emerging vaccine manufacturing 
technologies, the following 6 metrics were developed and applied to each of these 
technology: (1) technology readiness, (2) technological complexity, (3) ease of up- or out-
scalability, (4) flexibility, universal applicability for the manufacturing of a wide range of 
vaccines, (5) stability of the vaccine product at tropical ambient temperatures, and (6) 
speed of response from the identification of the nucleic acid sequence of a new threat 
antigen to vaccine deployment. For each of these 6 metrics, a rating from 1 (indicating 
challengingness or high risk) to 5 (indicating attainability with up to 5 years of R&D) was 
provided, based on information available in the literature and the expertise of the authors 
in vaccinology, molecular and cellular biology and manufacturing process development. 
Results from this risk and feasibility estimate rating are presented in Table 2 below.  
For the technology readiness metric, the highest rating of 5 was allocated to the GMMA 
vaccines since regulatory-approved OMV vaccines exist [33,34], GMP grade GMMA production 
has already been described at pilot scale [80] , and GMMA vaccines have passed phase 1 
(NCT03089879) and phase 2a (NCT02676895), and are now entering phase 2 clinical trials 
(NCT03527173). Thus, this technology appears mature enough for production-scale 
implementation within 5 years. The RNA platform comes in at 4, as RNA vaccines have 
reached phase 2 and 3 clinical trials and have been produced at pilot scale. The yeast 
platform was rated at 2 for technology readiness because although human glycosylation in 
yeast has been previously reported [52], human glycosylation has not yet been successfully 
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implemented for humanized protein biomanufacturing in yeast. Vaccine development using 
this yeast platform is at the R&D stage however, yeast-based production-scale fermentation 
technologies are well-established. The ADDomerTM platform is rated at 3.  Although the 
ADDomerTM multiprotein has only been produced at lab scale, and ADDomerTM based 
vaccines are in pre-clinical development, the insect cell-baculovirus platform has already 
been utilized for recombinant vaccine manufacturing. However, no ADDomer-based 
vaccines are yet subjected to clinical trials, thus their potential utility will require clinical 
evaluation. 
The technological complexity metric assesses risks that can hinder the manufacturing 
process due to contamination by faster-growing micro-organisms, due to unstable products 
and production intermediates, or due to complex downstream processes. For this metric, 1 
was allocated to the ADDomerTM platform due to bacterial and yeast contamination risks, 
and the GMMA platform was ranked at 5 since it is a bacterial manufacturing technology 
with simple downstream purification. The yeast platform was graded 3 for technological 
complexity since yeast-based manufacturing is robust, however: (i) it is still susceptible to 
bacterial contamination, (ii) the downstream purification is relatively complex, and (iii) the 
highly-engineered yeast might be sensitive to changes in culture conditions. The 
technological complexity of the RNA platform was estimated at 2, due to: (1) the relatively 
high degradation risk in the mid-stream process and downstream purification, due to 
contamination with RNAse or hydrolysis, and (2) sensitive enzymatic reactions. 
For ease of up- or out-scaling, the GMMA platform was ranked at 5, since bacterial cells are 
robust and because the bioprocessing and downstream processing are simple and robust. 
The yeast platform was ranked at 4 for scalability since the robustness of these micro-
organisms allows up-scaling, but the complexity of the downstream process increases the 
difficulty of both out- and up-scaling. The RNA platform was ranked at 3 for ease of scaling 
because the enzymatic reactions are in principle up- and out-scalable, and because the 
downstream purification is less complex than that of the GMMA or yeast platform. However, 
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the ability for sustainable manufacture of long replicon RNA at scale has yet to be 
demonstrated. The ADDomerTM platform was ranked at 3 for scalability because insect cells 
are fragile under higher pressures and shear rates compared to yeast and bacteria, thus 
limit up-scaling, and because the complexity of the downstream process increases the 
difficulty of both out- and up-scaling. 
In terms of flexibility, the technology with the highest rating of 5, within 5 years of R&D, can 
produce any kind of vaccines, including: proteins with human-like post-translational 
modifications (complex glycosylation), proteins embedded in lipid membranes, proteins in 
viral capsid-type complexes, proteins with bacteria-specific post-translational 
modifications, and bacterial polysaccharides. The low end of the flexibility spectrum, at 1, 
was attributed to technologies which can produce only one particular vaccine, and most, if 
not all, existing vaccine manufacturing technologies would fall under this rating. The RNA 
platform can express any type of protein antigen with the complex human glycosylation 
profile, however, it cannot produce bacterial polysaccharides and bacterial and parasite 
proteins are processed atypically, hence graded at 4 for flexibility. The yeast and 
ADDomerTM platforms are limited in producing bacterial polysaccharides, bacteria-specific 
post-translational modifications, and lipid membrane-embedded proteins, thus graded at 3. 
In contrast to humanized yeast expression, ADDomerTM molecules glycosylated post-
translationally inside the cell cannot be currently expressed at high yields. Contrarily, 
recombinant proteins expressed in humanized yeast might require assembly into VLPs or 
embedding into membranes to achieve immunogenicity levels readily induced by the 
ADDomerTM platform. The GMMA platform was graded at 2 for flexibility, because it cannot 
yield human-specific post-translational modifications and viral capsid-like multiprotein 
complexes. However out of these platforms, GMMA is the most suitable for bacterial 
vaccines. 
For thermostability, the high end of the scale, at 5, was set for vaccines which can have a 
half-life of at least 6 months at 40°C, with up to 5 years of R&D investment. ADDomerTM can 
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be stabilized with disulphide bonds to increase its thermostability between 37°C and 45°C 
for several months [57], thus it seems that grade 5 for ADDomerTM thermostability is 
achievable. GMMA is stable at room temperature for weeks, hence its thermostability was 
estimated at 3. Recombinant vaccines yielded by the yeast platform would have a wide 
range of thermostabilities, however, in general, could be formulated in thermostable 
products, thus their thermostability was estimated at 3. RNA molecules are relatively fragile 
and can undergo hydrolysis or transesterification, even in the absence of RNAse enzymes 
[117], hence graded at 2 for thermostability. However, substantially increasing the 
thermostability of RNA vaccines appears feasible using lyophilization or ionic liquids, since 
this has already been achieved for DNA and siRNA molecules [118,119]. Lyophilization and 
ionic liquids can also increase the thermostability of the other vaccines presented here. 
Thermostability is crucial especially in the last part of the delivery process to reach isolated 
communities in tropical areas, in the absence of a cold-chain [120,121]. 
For speed of response, the RNA platform is rated at 5, due to the ease and speed of 
generating custom DNA template and RNA replicon sequences. The ADDomerTM platform is 
rated at 4, due to rapid genetic design offered by the MultiBacTM system. The GMMA 
platform is rated at 2 for the speed of response since genetic re-engineering of these OMVs 
is time-consuming. The yeast platform is rated at 1, since it requires advanced genetic re-
programming and potentially generating a high-yield secretion cell line.  
Finally, a uniformly weighted overall feasibility and risk estimate was calculated by 
summing up the values for each metric along the columns in Table 2 for each technology. 
This way, the technologies in the order of increasing near-term feasibility and decreasing 
risk are: (1) yeast platform, (2) ADDomerTM platform, (3) RNA platform, (4) GMMA platform. 





Table 2. Feasibility and risk assessment of the 4 emerging platform technologies described 
in sections 3, 4, 5, and 6. 










1 Technology readiness 2 3 5 4 
2 Technological complexity 3 1 5 2 
3 Ease of scale-up and -out 4 2 5 3 
4 Flexibility b)  3 3 2 4 
5 Thermo-stability of product 3 5 3 2 
6 Speed of response 1 4 2 5 
Sum: overall feasibility and risk 
estimate c) 
16 18 22 20 
a)
 Yeast platform - Humanised, high-yield yeast platform for recombinant vaccine 
manufacturing; ADDomerTM platform - Insect cell-baculovirus platform for recombinant 
vaccine manufacturing; GMMA platform - Outer membrane vesicle vaccines, Generalized 
Modules for Membrane Antigen vaccine manufacturing; RNA platform - RNA vaccine 
manufacturing. 
b) Universal applicability for the manufacturing of a wide range of vaccines. 
c) The overall feasibility and risk estimate was calculated by summing up the values for 
each metric per technology. 
 
As part of the roadmap towards full-scale commercialization, the technical and economic 
feasibility of these vaccine platform technologies should be evaluated in detail by modelling, 
simulating and optimizing the manufacturing processes and their respective supply chains. 
Thus, additionally to the above described 6 metrics, the capital costs (consisting mostly of 
facility construction, equipment and machinery costs) and operational & maintenance costs 
(consisting mostly of the costs of raw materials and consumables, labour cost and utility 
costs) should also be computed.  For the techno-economically most viable vaccine platform 
technology, a pilot scale facility should be constructed, which can produce a wide range of 
high-demand or currently costly vaccines at low costs for clinical trials. To satisfy vaccine 
demands and to further reduce manufacturing costs, a production scale facility should 
subsequently be constructed. The profits should be reinvested in constructing more 






Existing vaccine manufacturing technologies have been reviewed and the following four 
promising future vaccine manufacturing technologies were evaluated: (1) humanised, high-
yield yeast platform, (2) insect cell-baculovirus ADDomerTM platform, (3) GMMA vaccine 
platform; (4) RNA vaccine platform. The strengths and weaknesses of each of the 4 vaccine 
manufacturing platform technologies were assessed using the 6 metrics of technology 
readiness, technological complexity, ease of scale-up, flexibility, thermo-stability of product, 
and speed of response. This way, a detailed comparative picture of these 4 vaccine 
manufacturing platform technologies was obtained and based on this analysis measures can 
be taken to improve these vaccine platform technologies. The 4 emerging technologies were 
ordered by decreasing near-term feasibility and increasing risk as: (1) GMMA platform, (2) 
RNA platform, (3) ADDomerTM platform, (4) yeast platform. Future work is needed and 
being carried out to more accurately evaluate the techno-economic feasibility of these 
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Figure 2. Operation scheme for the manufacturing of protein vaccines in humanised, high-
yield yeast and in insect cell platforms. A. Recombinant protein vaccines production in 
humanised, high-yield yeast. Human-like complex glycosylation has been reported in yeast 
[52], however, this and high-yield secretion is not yet implemented at production-scale [7,52–
54]. B. Bio-manufacturing of recombinant ADDomerTM multi-antigen vaccines using the 
MultiBacTM insect cell–baculovirus expression system [55–57]. The process was scaled up here 
based on recombinant HA protein expression for influenza vaccine manufacturing [10,58,59]. 
The grey arrows indicate the feeding back of excess insect cells from the 2500 L production 




Figure 3. Operation scheme for the manufacturing of Generalized Modules for Membrane 
Antigens (GMMA) and RNA vaccines. A. GMMA vaccine production using gram-negative 
bacteria. GMMA are released constantly during bacterial culture and are separated using 
two sequential TFF steps [80]. B. RNA vaccine production using in vitro transcription. The 
self-replicating RNA, which encodes the antigen of interest, is transcribed from a DNA 
template using in vitro transcription, 5’ capped co-transcriptionally, the template DNA is 
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